Matches in SemOpenAlex for { <https://semopenalex.org/work/W3037343016> ?p ?o ?g. }
- W3037343016 endingPage "596" @default.
- W3037343016 startingPage "596" @default.
- W3037343016 abstract "Avanafil (AVA) is a second-generation phosphodiesterase-5 (PDE5) inhibitor. AVA shows high selectivity to penile tissues and fast absorption, but has a bioavailability of about 36%. The aim was to formulate and optimize AVA-biodegradable nanoparticles (NPs) to enhance AVA bioavailability. To assess the impact of variables, the Box-Behnken design was utilized to investigate and optimize the formulation process variables: the AVA:poly (lactic-co-glycolic acid) (PLGA) ratio (w/w, X1); sonication time (min, X2); and polyvinyl alcohol (PVA) concentration (%, X3). Particle size (nm, Y1) and EE% (%, Y2) were the responses. The optimized NPs were characterized for surface morphology and permeation. Furthermore, a single-oral dose (50 mg AVA) pharmacokinetic investigation on healthy volunteers was carried out. Statistical analysis revealed that all the investigated factors exhibited a significant effect on the particle size. Furthermore, the entrapment efficiency (Y2) was significantly affected by both the AVA:PLGA ratio (X1) and PVA concentration (X3). Pharmacokinetic data showed a significant increase in the area under the curve (1.68 folds) and plasma maximum concentration (1.3-fold) for the AVA NPs when compared with raw AVA. The optimization and formulation of AVA as biodegradable NPs prepared using solvent evaporation (SE) proves a successful way to enhance AVA bioavailability." @default.
- W3037343016 created "2020-07-02" @default.
- W3037343016 creator A5074675838 @default.
- W3037343016 creator A5075547237 @default.
- W3037343016 creator A5080103720 @default.
- W3037343016 creator A5081642528 @default.
- W3037343016 date "2020-06-26" @default.
- W3037343016 modified "2023-09-23" @default.
- W3037343016 title "Formulation and Optimization of Avanafil Biodegradable Polymeric Nanoparticles: A Single-Dose Clinical Pharmacokinetic Evaluation" @default.
- W3037343016 cites W1536081943 @default.
- W3037343016 cites W1915246417 @default.
- W3037343016 cites W1944257356 @default.
- W3037343016 cites W1966911390 @default.
- W3037343016 cites W1968912335 @default.
- W3037343016 cites W1973572872 @default.
- W3037343016 cites W1974933001 @default.
- W3037343016 cites W1984158434 @default.
- W3037343016 cites W1994299829 @default.
- W3037343016 cites W2001018507 @default.
- W3037343016 cites W2013822681 @default.
- W3037343016 cites W2013971224 @default.
- W3037343016 cites W2017317942 @default.
- W3037343016 cites W2017451930 @default.
- W3037343016 cites W2024735368 @default.
- W3037343016 cites W2027353500 @default.
- W3037343016 cites W2030430991 @default.
- W3037343016 cites W2039447561 @default.
- W3037343016 cites W2041985711 @default.
- W3037343016 cites W2045819626 @default.
- W3037343016 cites W2051087357 @default.
- W3037343016 cites W2062063474 @default.
- W3037343016 cites W2063755160 @default.
- W3037343016 cites W2066354221 @default.
- W3037343016 cites W2067496698 @default.
- W3037343016 cites W2069016591 @default.
- W3037343016 cites W2070725646 @default.
- W3037343016 cites W2076260569 @default.
- W3037343016 cites W2077640736 @default.
- W3037343016 cites W2080552945 @default.
- W3037343016 cites W2087996347 @default.
- W3037343016 cites W2129959640 @default.
- W3037343016 cites W2132879097 @default.
- W3037343016 cites W2172902239 @default.
- W3037343016 cites W2200340609 @default.
- W3037343016 cites W2286638177 @default.
- W3037343016 cites W2300043713 @default.
- W3037343016 cites W2325693563 @default.
- W3037343016 cites W2345127954 @default.
- W3037343016 cites W2461909646 @default.
- W3037343016 cites W2534758754 @default.
- W3037343016 cites W2579967207 @default.
- W3037343016 cites W2583093292 @default.
- W3037343016 cites W2762341360 @default.
- W3037343016 cites W2763859085 @default.
- W3037343016 cites W2794121764 @default.
- W3037343016 cites W2897974385 @default.
- W3037343016 cites W2902634101 @default.
- W3037343016 cites W2903190156 @default.
- W3037343016 cites W2972776906 @default.
- W3037343016 cites W2987847061 @default.
- W3037343016 cites W3015783759 @default.
- W3037343016 cites W3029164387 @default.
- W3037343016 cites W344335130 @default.
- W3037343016 cites W4210978570 @default.
- W3037343016 doi "https://doi.org/10.3390/pharmaceutics12060596" @default.
- W3037343016 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7356025" @default.
- W3037343016 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32604853" @default.
- W3037343016 hasPublicationYear "2020" @default.
- W3037343016 type Work @default.
- W3037343016 sameAs 3037343016 @default.
- W3037343016 citedByCount "5" @default.
- W3037343016 countsByYear W30373430162021 @default.
- W3037343016 countsByYear W30373430162023 @default.
- W3037343016 crossrefType "journal-article" @default.
- W3037343016 hasAuthorship W3037343016A5074675838 @default.
- W3037343016 hasAuthorship W3037343016A5075547237 @default.
- W3037343016 hasAuthorship W3037343016A5080103720 @default.
- W3037343016 hasAuthorship W3037343016A5081642528 @default.
- W3037343016 hasBestOaLocation W30373430161 @default.
- W3037343016 hasConcept C104628117 @default.
- W3037343016 hasConcept C112705442 @default.
- W3037343016 hasConcept C125287762 @default.
- W3037343016 hasConcept C13965031 @default.
- W3037343016 hasConcept C147789679 @default.
- W3037343016 hasConcept C150077022 @default.
- W3037343016 hasConcept C155672457 @default.
- W3037343016 hasConcept C159985019 @default.
- W3037343016 hasConcept C170295934 @default.
- W3037343016 hasConcept C171250308 @default.
- W3037343016 hasConcept C178790620 @default.
- W3037343016 hasConcept C181389837 @default.
- W3037343016 hasConcept C185592680 @default.
- W3037343016 hasConcept C187530423 @default.
- W3037343016 hasConcept C192562407 @default.
- W3037343016 hasConcept C2778551929 @default.
- W3037343016 hasConcept C2780165375 @default.
- W3037343016 hasConcept C41625074 @default.
- W3037343016 hasConcept C43617362 @default.